Mammary Cell News Volume 5.00 | Jan 3 2013

LABORATORY RESEARCH

Unbiased Quantitative Assessment of Her-2 Expression of Circulating Tumor Cells in Patients with Metastatic and Non-Metastatic Breast Cancer
Expression of Her-2 on circulating tumor cells was determined by a manual review and an automated algorithm using Her-2- fluorescein isothiocyanate fluorescence of leukocytes to determine the Her-2-expression threshold in each sample. [Ann Oncol] Abstract

Suppression of FOXQ1 in Benzyl Isothiocyanate-Mediated Inhibition of Epithelial-Mesenchymal Transition in Human Breast Cancer Cells
Loss of E-cadherin expression and induction of mesenchymal markers are biochemical hallmarks of epithelial-to-mesenchymal transition (EMT), a developmental process implicated in progression of cancer to aggressive state. Researchers offer novel insights into the mechanism by which benzyl isothiocyanate inhibits EMT. [Carcinogenesis] Abstract

Fucoidan Induces Changes in the Epithelial-Mesenchymal Transition and Decreases Metastasis by Enhancing Ubiquitin-Dependent TGFβ Receptor Degradation in Breast Cancer
Using 4T1 and MDA-MB-231 cells, the authors found that fucoidan effectively reverses TGFβ receptor-induced epithelial-mesenchymal transition morphological changes, up-regulates epithelial markers, down-regulates mesenchymal markers, and decreases the expression of transcriptional repressors Snail, Slug, and Twist. [Carcinogenesis] Abstract

Neutralization of Prolactin Receptor Function by Monoclonal Antibody LFA102, a Novel Potential Therapeutic for the Treatment of Breast Cancer
Scientists describe the biological properties of LFA102, a humanized neutralizing monoclonal antibody directed against the extracellular domain of the prolactin receptor. [Mol Cancer Ther] Abstract

The Tyrosine Kinase Inhibitor E-3810 Combined with Paclitaxel Inhibits the Growth of Advanced- Stage Triple-Negative Breast Cancer Xenografts
Researchers investigated the activity of E-3810 combined with different cytotoxic agents in a MDA-MB-231 triple-negative breast cancer xenograft model. [Mol Cancer Ther] Abstract

Distinct Phospho-Tyrosine Dependent Functions of ShcA Are Required for TGFβ-Induced Breast Cancer Cell Migration, Invasion and Metastasis
Through a structure/function approach, investigators showed that the PTB, but not the SH2 domain, of ShcA is required for transforming growth factor beta (TGFβ)-induced migration and invasion of ErbB2-expressing breast cancer cells. [J Biol Chem] Abstract | Full Article

Cyclooxygenase-2 Enzyme Induces the Expression of the α-2,3-Sialyltransferase-3 (ST3Gal-I) in Breast Cancer
Using the breast cancer cell line T47D, researchers showed that PGE2, one of the final products of the cyclooxygenase-2 pathway, can induce the mRNA expression of the sialyltransferase ST3Gal-I, resulting in increased sialyltransferase activity, demonstrated by a reduction in PNA lectin staining. [J Biol Chem] Abstract

The Prognostic Impact of Circulating Tumor Cells in Subtypes of Metastatic Breast Cancer
Researchers aimed to assess the impact of circulating tumor cells on overall survival and progression free survival in patients with predefined molecular subgroups of metastatic breast cancer. [Breast Cancer Res Treat] Abstract

Estrogen Receptor and Progesterone Receptor Expression in Normal Terminal Duct Lobular Units Surrounding Invasive Breast Cancer
Scientists evaluated relationships of breast cancer risk factors and tumor pathology to estrogen receptor and progesterone receptor expression in terminal duct lobular units surrounding breast cancers. [Breast Cancer Res Treat] Abstract

CLINICAL RESEARCH

Risk of Asynchronous Contralateral Breast Cancer in Noncarriers of BRCA1 and BRCA2 Mutations with a Family History of Breast Cancer: A Report from the Women’s Environmental Cancer and Radiation Epidemiology Study
From their population-based case-control study comparing women with contralateral breast cancer (CBC) to women with unilateral breast cancer, researchers selected women who tested negative for BRCA1 and BRCA2 mutations. Rate ratios and 95% CIs were estimated to examine the association between family history of breast cancer and risk of asynchronous CBC. [J Clin Oncol] Abstract

Risk of Myelodysplastic Syndrome and Acute Myeloid Leukemia Post Radiation Treatment for Breast Cancer: A Population-Based Study
The authors hypothesized that breast cancer radiation treatment is associated with increased risk of myelodysplastic syndromes and acute myeloid leukemia as seen in a previously conducted study. [Breast Cancer Res Treat] Abstract

Sphingotec Announces Launch of Blood Test for Breast Cancer Prediction
Sphingotec GmbH announced that it will launch a blood test for the early prediction of breast cancer in women. The test will be available in Europe beginning in the second quarter of 2013. [PR Newswire Association LLC] Press Release

Dune Medical Devices Receives FDA Approval for Breakthrough Advancement in Breast Cancer Surgery
Dune Medical Devices, Inc. announced that its breakthrough intra-operative tissue assessment tool for early-stage breast cancer surgery, the MarginProbe System, has received Premarket Approval by the United States Food and Drug Administration (FDA). [Dune Medical Devices] Press Release

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

NEW 17th Annual Hilton Head Workshop: Regenerative Medicine – Technologies Enabling Novel Therapies
March 20-23, 2013
Hilton Head Island, United States

Visit our events page to see a complete list of events in the mammary cell community.

Scientist or Engineer – hPSC Bioengineer (STEMCELL Technologies, Inc.)

MSc – Future Opportunities (STEMCELL Technologies, Inc.)

PhD – Future Opportunities (STEMCELL Technologies, Inc.)

Postdoctoral Position – Tumor Stem Cells (Cancer Institute of New Jersey)

Assistant Professor – Breast Cancer (Cedars-Sinai Medical Center)

Principal Investigator – Cancer Research (Institut de Recherches Cliniques de Montréal)

Postdoctoral Position – Genetic Biomarkers in Breast Cancer (Rush University Medical Center)

PhD Studentship – Integrated Classification of Breast Cancers to Optimize Treatment Protocols (Radboud University Nijmegen Medical Centre)

Postdoctoral Position – Gene Regulation in Breast Cancer/Stem Cell Biology (UC College of Medicine)

Postdoctoral Position/PhD Student – Resistance to Anti-Cancer Drug Therapy (The Netherlands Cancer Institute)

Laboratory Technician/Manager Position – MicroRNA Cancer Biology (Thomas Jefferson University)

Recruit Top Talent: Reach more than 55,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.